טוען...
Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab
BACKGROUND: Preliminary evidence indicates that early tumor shrinkage (ETS) following immune checkpoint inhibitor (ICI) initiation may be associated with survival outcomes in patients with advanced melanoma. ETS has not been explored as a biomarker of survival outcomes or patient-reported outcomes i...
שמור ב:
| הוצא לאור ב: | J Immunother Cancer |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BMJ Publishing Group
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7279663/ https://ncbi.nlm.nih.gov/pubmed/32503948 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000500 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|